Purple Biotech Ltd PPBT
Set alert
1.17 USD +0.09 +8.33%
At close · Oct 30
1.17 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
1.07 Day range 1.17
0.924 52-week range 9.40
- YTD
- -82.22%
- 1 year
- -87.55%
- Open
- 1.09
- Prev close
- 1.08
- Mkt cap
- 1.90M
- Vol
- 41.62K
- Avg vol
- 1.28M
- EPS
- -47.64
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.07
- High
- 1.17
- Forward P/E
- -1.69
- Beta
- 0.38
- Short ratio
- 0.43
- Inst. own
- 9.33%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.64
- 200-d avg
- 8.21
- 1y target
- 33.00
2Y chart
Events in this range
- Nov 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 15, 2024Earnings: -1.37; estimate -1.2; surprise -14.17%
- Mar 2, 2026Split: 1 for 10
Signals (67)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2026 | 2 days ago |
| RSI: Oversold | Oct 26, 2026 | 6 days ago |
| RSI: Oversold | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Oct 16, 2026 | 2 weeks ago |
| SMA: Bearish | Sep 16, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 15, 2026 | 1 month ago |
| RSI: Overbought | Sep 2, 2026 | 2 months ago |
| RSI: Oversold | Jul 21, 2026 | 3 months ago |
| RSI: Oversold | Jul 13, 2026 | 3 months ago |
| RSI: Oversold | Jul 7, 2026 | 3 months ago |
| RSI: Oversold | Jun 30, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 11, 2026 | 4 months ago |
| RSI: Oversold | Jun 11, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 4, 2026 | 5 months ago |
| RSI: Oversold | May 20, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 30, 2026 | 6 months ago |
| SMA: Bearish | Apr 29, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 20, 2026 | 7 months ago |
| RSI: Oversold | Mar 12, 2026 | 7 months ago |
| RSI: Oversold | Feb 27, 2026 | 8 months ago |
| RSI: Oversold | Feb 20, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 19, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 11, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 30, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 23, 2026 | 9 months ago |
| RSI: Oversold | Jan 20, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 14, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 8, 2026 | 9 months ago |
| SMA: Bearish | Dec 18, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 9, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 24, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 17, 2025 | 11 months ago |
| SMA: Bullish | Nov 3, 2025 | 12 months ago |
| SMA: Bearish | Oct 31, 2025 | 1 year ago |
| SMA: Bullish | Oct 29, 2025 | 1 year ago |
| RSI: Overbought | Oct 29, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 22, 2025 | 1 year ago |
| RSI: Oversold | Sep 2, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 29, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 14, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 28, 2025 | 1 year ago |
| SMA: Bearish | Jul 25, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| SMA: Bearish | Jul 11, 2025 | 1 year ago |
| SMA: Bullish | Jul 9, 2025 | 1 year ago |
| SMA: Bearish | Jul 8, 2025 | 1 year ago |
| SMA: Bullish | Jul 3, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 3, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 13, 2025 | 1 year ago |
| SMA: Bearish | Jun 12, 2025 | 1 year ago |
| SMA: Bullish | May 30, 2025 | 1 year ago |
| MACD: Buy Signal | May 19, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 30, 2025 | 1 year ago |
| SMA: Bearish | Apr 23, 2025 | 1 year ago |
| SMA: Bullish | Apr 17, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 15, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 7, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 17, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 27, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 18, 2025 | 1 year ago |
| SMA: Bearish | Jan 17, 2025 | 1 year ago |
| SMA: Bullish | Jan 16, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 7, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 31, 2024 | 1 year ago |
| RSI: Overbought | Dec 2, 2024 | 1 year ago |
Key statistics
- Market cap
- 9.56M
- Enterprise value
- 695.00M
- Trailing P/E
- 0.00
- Forward P/E
- -1.69
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 27.21
- EPS (TTM)
- -8.10
- Beta
- 0.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -8.88M
- Total cash
- 7.39M
- Total debt
- 261.00K
- Return on equity
- -44.67%
- Shares outstanding
- 2.58M
- Short % of float
- 1.33%
- 50-day average
- 3.64
- 200-day average
- 8.21
Analyst view
Consensus: none
Price target (mean) 33.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.22.
Financials — quick view
PPBT Revenue — quarterly 0
PPBT Net income — quarterly -441.00K
PPBT EPS — quarterly -0.40
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 15, 2024 | Sep 1, 2024 | -1.20 | -1.37 | -0.17 | -14.17% |
| Aug 16, 2024 | Jun 1, 2024 | -2.60 | -1.60 | +1.00 | +38.46% |
| May 21, 2024 | Mar 1, 2024 | -3.00 | -3.00 | 0.00 | 0.00% |
| Mar 5, 2024 | Dec 1, 2023 | -3.40 | -6.40 | -3.00 | -88.24% |
| Nov 21, 2023 | Sep 1, 2023 | -4.40 | -4.20 | +0.20 | +4.55% |
| Aug 22, 2023 | Jun 1, 2023 | -5.00 | -4.60 | +0.40 | +8.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 20, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 19, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- purple-biotech.com
News
- Purple Biotech’s Abstract On IM1240, Lead Tri-Specific Antibody From CAPTN-3 Platform, Accepted For Oral Presentation At 38th EORTC-NCI-AACR Symposium
- Purple Biotech Announces IM1240 Abstract Selected for Oral Presentation at the 38th EORTC-NCI-AACR Symposium
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Crude Oil Moves Higher; US Factory Orders Rise In July
- Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings
- Why Is Purple Biotech Stock Gaining Wednesday?
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Purple Biotech Issued Patent From U.S. Patent And Trademark Office For Its Application Covering Tri-Specific Antibody Constructs, Models
- New U.S. Patent Allowance Strengthens Protection for CAPTN-3 Modular Platform for Next-Generation Multispecific Antibodies
Your note
Sign in to keep a note on PPBT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 12.10% | 158,000 | 584.60K | Sep 29, 2024 |
| Morgan Stanley | 0.62% | 8,055 | 29.80K | Sep 29, 2024 |
| BNP Paribas Financial Markets | 0.28% | 3,675 | 13.60K | Sep 29, 2024 |
| Td Waterhouse Canada Inc. | 0.02% | 200 | 740 | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.02% | 254 | 939 | Sep 29, 2024 |
| Royal Bank of Canada | 0.01% | 107 | 395 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.05% | 633 | 2.34K | Oct 30, 2024 |